Axsome Therapeutics (NASDAQ:AXSM) has been assigned a $5.00 price objective by stock analysts at LADENBURG THALM/SH SH in a research note issued on Wednesday, The Fly reports. The brokerage presently has a “buy” rating on the stock. LADENBURG THALM/SH SH’s price objective points to a potential upside of 21.95% from the stock’s previous close.
AXSM has been the topic of several other research reports. Zacks Investment Research raised Axsome Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, July 25th. HC Wainwright set a $10.00 price target on Axsome Therapeutics and gave the company a “buy” rating in a research note on Tuesday, October 9th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $10.10.
Shares of NASDAQ:AXSM opened at $4.10 on Wednesday. Axsome Therapeutics has a 1-year low of $2.05 and a 1-year high of $5.95. The company has a market cap of $90.57 million, a PE ratio of -3.28 and a beta of -0.15. The company has a current ratio of 2.26, a quick ratio of 2.26 and a debt-to-equity ratio of 0.74.
A hedge fund recently bought a new stake in Axsome Therapeutics stock. A.R.T. Advisors LLC purchased a new stake in Axsome Therapeutics Inc (NASDAQ:AXSM) during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 59,282 shares of the company’s stock, valued at approximately $145,000. A.R.T. Advisors LLC owned approximately 0.23% of Axsome Therapeutics at the end of the most recent reporting period. 15.63% of the stock is currently owned by hedge funds and other institutional investors.
About Axsome Therapeutics
Axsome Therapeutics, Inc, a clinical stage biopharmaceutical company, is developing novel therapies for central nervous system (CNS) disorders. Its product candidate portfolio includes AXS-05, AXS-09, AXS-02, AXS-07, and AXS-06. AXS-05 is in the Phase III clinical trial in treatment resistant depression and in agitation associated with Alzheimer's disease, as well as in the Phase II clinical trial for smoking cessation.
See Also: What are Closed-End Mutual Funds?
Receive News & Ratings for Axsome Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.